AR and prostate cancer: Recently, [18F]enzalutamide was evaluated in prostate cancer xenografts, demonstrating high specificity and stability as an AR-targeted tracer, suggesting that [18F]enzalutamide could potentially be adapted for imaging androgen receptors in breast cancer [187].